Judes Gaëlle, Dagdemir Aslihan, Karsli-Ceppioglu Seher, Lebert André, Echegut Maureen, Ngollo Marjolaine, Bignon Yves-Jean, Penault-Llorca Frédérique, Bernard-Gallon Dominique
Department of Oncogenetics, Centre Jean Perrin, CBRV, 28 Place Henri Dunant, 63001 Clermont-Ferrand, France.
EA 4677 'ERTICA', University of Auvergne, 63011 Clermont-Ferrand, France.
Epigenomics. 2016 Jul;8(7):909-24. doi: 10.2217/epi-2016-0015. Epub 2016 Jul 18.
Here, we investigated how the St Gallen breast molecular subtypes displayed distinct histone H3 profiles.
PATIENTS & METHODS: 192 breast tumors divided into five St Gallen molecular subtypes (luminal A, luminal B HER2-, luminal B HER2+, HER2+ and basal-like) were evaluated for their histone H3 modifications on gene promoters.
ANOVA analysis allowed to identify specific H3 signatures according to three groups of genes: hormonal receptor genes (ERS1, ERS2, PGR), genes modifying histones (EZH2, P300, SRC3) and tumor suppressor gene (BRCA1). A similar profile inside high-risk cancers (luminal B [HER2+], HER2+ and basal-like) compared with low-risk cancers including luminal A and luminal B (HER2-) were demonstrated.
The H3 modifications might contribute to clarify the differences between breast cancer subtypes.
在此，我们研究了圣加仑乳腺癌分子亚型如何呈现出不同的组蛋白H3谱。
对192例分为五种圣加仑分子亚型（腔面A型、腔面B型HER2阴性、腔面B型HER2阳性、HER2阳性和基底样型）的乳腺肿瘤进行基因启动子上组蛋白H3修饰的评估。
方差分析能够根据三组基因确定特定的H3特征：激素受体基因（雌激素受体1、雌激素受体2、孕激素受体）、修饰组蛋白的基因（EZH2、P300、SRC3）和肿瘤抑制基因（BRCA1）。与包括腔面A型和腔面B型HER2阴性在内的低风险癌症相比，高风险癌症（腔面B型HER2阳性、HER2阳性和基底样型）呈现出相似的特征。
H3修饰可能有助于阐明乳腺癌亚型之间的差异。
